Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.

@article{Du2013IntrapleuralCT,
  title={Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.},
  author={Nan Du and Xiaosong Li and Fang Li and Hui Zhao and Zhongyi Fan and Junxun Ma and Yan Fu and Huanrong Kang},
  journal={Oncology reports},
  year={2013},
  volume={29 6},
  pages={
          2332-40
        }
}
Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC). Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid. However, whether intrapleural delivery of bevacizumab can be used to treat MPE remains unknown. The aim of the present study was to evaluate the efficacy and safety of combined intrapleural therapy with bevacizumab… CONTINUE READING
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 27 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 53 REFERENCES

Similar Papers

Loading similar papers…